CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice

Journal of Reproductive Immunology

Volumn 68, Issue 1-2, 2005, Pages 53-69

  Tengvall, Sara ^a   Josefsson, Agnetha ^a   Holmgren, Jan ^a   Harandi, Ali M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

CpG; DNA vaccine; Genital herpes; HSV

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN D; IMMUNOGLOBULIN G2; OLIGODEOXYNUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SCREENING; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; IN VITRO STUDY; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL;

ANIMALS; CPG ISLANDS; FEMALE; HERPES GENITALIS; MICE; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 28444491927     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2005.06.010     Document Type: Article

References (33)

1. A.A. Ashkar, S. Bauer, W.J. Mitchell, J. Vieira, and K.L. Rosenthal Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2 J. Virol. 77 2003 8948 8956
2. D.I. Bernstein, and L.R. Stanberry Herpes simplex virus vaccines Vaccine 17 1999 1681 1689
3. N. Bourne, G.N. Milligan, M.R. Schleiss, D.I. Bernstein, and L.R. Stanberry DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2 Vaccine 14 1996 1230 1234
4. L. Corey, A.G. Langenberg, R. Ashley, R.E. Sekulovich, A.E. Izu, J.M.J. Douglas, H.H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A.A. Adimora, P. Leone, C.L. Dekker, R.L. Burke, W.P. Leong, and S.E. Straus Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. Two randomized controlled trials JAMA 282 1999 331 340
5. R.J. DiPaolo, and E.R. Unanue Chemical dominance does not relate to immunodominance: studies of the CD4+ T cell response to a model antigen J. Immunol. 169 2002 1 4
6. A.M. Eis-Hübinger, D.S. Schmidt, and K.E. Schneweis Anti-glycoprotein B monoclonal antibody protects T cell-depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes J. Gen. Virol. 74 1993 379 385
7. S.K. Eo, S. Lee, S. Chun, and B.T. Rouse Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines J. Virol. 75 2001 569 578
8. A.M. Harandi The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges J. Clin. Virol. 30 2004 207 210
9. A.M. Harandi, and J. Holmgren CpG DNA as potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections Curr. Opin. Invest. Drugs 5 2004 141 145
10. A.M. Harandi, K. Eriksson, and J. Holmgren A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection J. Virol. 77 2003 953 962
11. A.M. Harandi, B. Svennerholm, J. Holmgren, and K. Eriksson Differential roles of B-cells and IFN-g-secreting CD4+ T-cells in innate and adaptive immune control of genital HSV-2 infection in mice J. Gen. Virol. 82 2001 845 853
12. A.M. Harandi, B. Svennerholm, J. Holmgren, and K. Eriksson Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity J. Virol. 75 2001 6705 6709
13. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira A Toll-like receptor recognizes bacterial DNA Nature 408 2000 740 745
14. Y. Hoshino, S.K. Dalai, K. Wang, L. Pesnicak, T.Y. Lau, D.M. Knipe, J.I. Cohen, and S.E. Straus Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs J. Virol. 79 2005 410 418
15. G.R. Kinghorn Epidemiology of genital herpes J. Int. Med. Res. 22 1994 14A 23A
16. D.M. Koelle, and L. Corey Recent progress in herpes simplex virus immunobiology and vaccine research Clin. Microbiol. Rev. 16 2003 96 113
17. A. Krieg CpG motifs in bacterial DNA and their immune effects Ann. Rev. Immunol. 20 2002 709 760
18. A. Krieg, and H. Davis Enhancing vaccine with immune stimulatory CpG DNA Curr. Opin. Mol. Ther. 3 2001 15 24
19. J.D. Kriesel, S.L. Spruance, R.A. Daynes, and B.A. Araneo Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease J. Infect. Dis. 173 1996 536 541
20. N. Kuklin, M. Daheshia, K. Karem, E. Manickan, and B.T. Rouse Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization J. Virol. 71 1997 3138 3145
21. S. Lee, M. Gierynska, S.K. Eo, N. Kuklin, and B.T. Rouse Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus Microb. Infect. 5 2003 571 578
22. Y. Lee, S.K. Eo, R.J. Rouse, and B.T. Rouse Influence of CCR7 ligand DNA preexposure on the magnitude and duration of immunity Virology 312 2003 169 180
23. L. Liu, X. Zhou, J. Shi, X. Xie, and Z. Yuan Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin Immunology 110 2003 341 347
24. W.L. McClements, M.E. Armstrong, R.D. Keys, and M.A. Liu Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease Proc. Natl. Acad. Sci. U.S.A. 93 1996 11414 11420
25. G.N. Milligan, and D.I. Bernstein Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract Virology 229 1997 259 268
26. L. Naesens, and E. De Clercq Recent developments in herpesvirus therapy Herpes 8 2001 12 16
27. M.B. Parr, and E.L. Parr The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice Virology 258 1999 282 294
28. M.B. Parr, and E.L. Parr Vaginal immunity in the HSV-2 mouse model Int. Rev. Immunol. 22 2003 43 63
29. R.B. Pyles, D. Higgins, C. Chalk, A. Zalar, J. Eiden, C. Brown, G. Van Nest, and L.R. Stanberry Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection J. Virol. 76 2002 11387 11396
30. J.I. Sin, J.J. Kim, J.D. Boyer, R.B. Ciccarelli, T.J. Higgins, and D.B. Weiner In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model J. Virol. 73 1999 501 509
31. J.I. Sin, J.J. Kim, R.L. Arnold, K.E. Shroff, D. McCallus, C. Patchuk, S.P. McElhiney, M.W. Wolf, S.J. Pompa-de Bruin, T.J. Higgins, R.B. Ciccarelli, and D.B. Weiner IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge J. Immunol. 162 1999 2912 2921
32. R. Weeratna, C.L. Brazolot Millan, A.M. Krieg, and H.L. Davis Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides Antisense Nucl. Acid Drug Dev. 8 1998 351 356
33. A.-K. Yi, M. Chang, D. Peckham, A. Krieg, and R. Ashman CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry J. Immunol. 160 1998 5898 5906